4 results
Determine the efficacy of atDCS as compared to ctDCS and sham stimulation in the improvement of executive functioning in PD-MCI.
To determine the maximum tolerated dose, dose limiting toxicity and recommended Phase 2 dose of BMS-753493 in subjects with advanced cancer.
POTENTIAL will be the first phase II RCT to assess the effects of combined cerebellar tDCS and VR-PFT in terms of outcomes at the level of body functions, activities and participation, as well as brain reorganization post stroke. Ultimately,…
The primary objective is to show a difference in responder rates between the study product (T4020) and the vehicle : a reduction of 50% or more in keratitis/ulcer area from baseline (inclusion visit = V2 = Day 0) assessed at Day 28 (Visit 6).